Itacitinib

Drug Profile

Itacitinib

Alternative Names: INCB-039110; INCB-039110-adipate; INCB39110

Latest Information Update: 21 Jul 2017

Price : $50

At a glance

  • Originator Incyte Corporation
  • Developer AstraZeneca; Incyte Corporation
  • Class Antineoplastics; Antipsoriatics; Antirheumatics; Small molecules
  • Mechanism of Action Janus kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Graft-versus-host disease
  • Phase II Hodgkin's disease; Non-small cell lung cancer
  • Phase I/II Non-Hodgkin's lymphoma; Solid tumours
  • Discontinued Myelofibrosis; Pancreatic cancer; Plaque psoriasis; Rheumatoid arthritis

Most Recent Events

  • 08 Jun 2017 Phase-III clinical trials in Graft-versus-host disease (Combination therapy, Treatment-naive) in United Kingdom, Turkey, Taiwan, Switzerland, Spain, Singapore, Portugal, Poland, New Zealand, Netherlands, South Korea, Italy, Israel, Hungary, Greece, Germany, France, Czech Republic, Canada, Belgium, Austria, Australia (PO) (NCT03139604)
  • 08 Jun 2017 Phase-III clinical trials in Graft-versus-host disease (Treatment-naive, Combination therapy) in USA (PO) (NCT03139604)
  • 15 May 2017 Incyte Corporation plans the phase III GRAVITAS-301 trial for Graft versus host disease (Combination therapy, Treatment-naive) (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top